Angiotensin receptor blockers and myocardial infarction

British Medical Journal

Volumn 329, Issue 7477, 2004, Pages 1248-1249

  Verma, Subodh ^a   Strauss, Marty ^b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b NORTH YORK GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; IRBESARTAN; LOSARTAN; METFORMIN; PHENFORMIN; PIOGLITAZONE; ROSIGLITAZONE; STATINE DERIVATIVE; TROGLITAZONE; VALSARTAN;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY BLOOD VESSEL; COUGHING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; EDITORIAL; FATALITY; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INCIDENCE; INFORMED CONSENT; INSULIN SENSITIVITY; KIDNEY FAILURE; LACTIC ACIDOSIS; LIVER NECROSIS; MORTALITY; OUTCOMES RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RECEPTOR BLOCKING; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STROKE;

EID: 9744237279     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.329.7477.1248     Document Type: Editorial

References (12)

1. Is GSK guilty of fraud? Lancet 2004;363:1919.
2. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
3. Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J. Heart outcomes prevention evaluation (HOPE) study. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001;358:2130-1.
4. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet 2003;362:772-6.
5. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 2003;362:777-81.
6. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.
7. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
8. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Much WE, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
9. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-60.
10. Levy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 2004;109:8-13.
11. Teo K, Yusuf S, Anderson C, Mookadarn F, Ramos B, Hilbrich L, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;148:52-61.
12. Strippoli GF, Craig M, Decks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828.